

Remarks

Claims 1 and 3-23 were pending.

Claims 1 and 6-11 are amended.


Claim 3 is canceled.

Claims 12, 16, 17 and 20 are original.

Claims 4, 5, 13-15, 18, 19 and 21-23 are as previously presented.

The application now contains claims 1 and 4-23.

Claim 1 is amended to delete (I) from line 1 and to insert the definition of L3 immediately following the definition of Q2. Support can be found on page 3 of the specification. Claim 1 is further amended for clarity by moving the definition of Q+X- from near the end of the claim to immediately following the definition for L3 and by inserting the phrase "and the group" immediately prior to the term "-L3(Q+X-)" which appears in the next line, and by inserting the phrase "in formula II" immediately following "-L3(Q+X-)". While word for word support may not be present for these descriptive phrases, their presence merely reinforces the meaning, imported earlier from original claim 2, that in the instant claims the group "-L3(Q+X-)" is present only in formula II and is equivalent to the group



It is noted that the group Q+X- may also appear as a substituent in places where it is not part of "-L3(Q+X-)".


Claims 6, 7, 8 and 10 are now independent. Claim 6 now recites the definitions for X⁻, R₅ and R₆ and claim 8 has been amended to define X⁻, R₅, R₆ and R₇, Q⁺X⁻. Support can be found in claim 1.

Claim 9 is now dependent upon claim 1. Claim 9 is also amended for clarity by moving the definition of T10 adjacent to the definition of T7. T10 appears in claim 9 only in formula Id1 which also contains T7.

Claim 11 is amended to insert the formula IVa (immediately following formula IIIe) and the definition of E1 (immediately following the definition of X-) in order to ensure that the compounds of now independent claim 6 are included in the process of claim 11. Support is found in original claim 11.

No new matter is added.


Applicants also offer the following remarks regarding the present Office Action. Applicants greatly appreciate the work and attention to detail exhibited in the present Action. However, a few statements therein are not accurate. Regarding claims 8 and 10, the Examiner states that formulae VIa and IIa1 through IIa4 are distinct from formula II in that they requires K1, K2 and K3 instead of a group L3. However, as explained above regarding claim 1, group "-L3(Q+X-)" of formula II is

equivalent to the group  that appears in formula VIa. Further regarding claim 10, the

Examiner questions whether claim 1 allows for the presence of ore than 1 carboxyl. Applicants respectfully point to the instant specification, page 5 lines 10-16 where examples of C2-25 alkylene interrupted by O, S etc, contain more than one oxygen. Applicants believe this shows that "interrupted by" allows for the interruption of more than moiety. However, in order to further prosecution, claims 8 and 10 have been made independent as discussed.

Applicants respectfully submit that all objections are addressed and are overcome and kindly ask that they be withdrawn and claims 1 and 4-23 found allowable. In the event that minor amendments will further prosecution, Applicants request that the examiner contact the undersigned representative.

Respectfully submitted,



Joseph C. Suhadolnik
Agent for Applicants
Reg. No. 56,880
filed under 37 CFR 1.34(a)

Ciba Specialty Chemicals Corporation
Patent Department
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
Tel. (914) 785-2973
Fax (914) 785-7102